This podcast was recorded on June 22, 2022. It is important to stay current with the latest data and recommendations regarding management of NSCLC.
Program Description
When involved in the treatment and management of patients with non-small cell lung cancer (NSCLC), managed care pharmacists must consider how use of predictive biomarkers can affect patient response to therapy. Several organizations recommend use of biomarker testing before initiating treatment for patients with NSCLC, and managed care professionals can ensure these recommendations are incorporated into treatment protocols. Evidence for first-line treatment regimens with immune checkpoint inhibitors (ICIs) will be presented, as well as considerations for managing immune-mediated adverse effects of therapy. This activity will also explore strategies managed care pharmacists can take to minimize the financial burden associated with use of ICIs in patients with NSCLC.
Target audience: Managed care pharmacists and oncology pharmacists
Type of activity: Knowledge
Release date: July 29, 2022
Expiration date: July 29, 2023
Time to complete activity: 0.5 hours
Fee: Free
Educational Objectives
At the completion of this activity, participants will be able to:
- Review the efficacy and safety of emerging frontline immune checkpoint inhibitors (ICIs) used as monotherapy and in combination regimens
- Indicate the impact of ICIs and programmed death-ligand 1 testing on cost-effectiveness and patient-reported outcomes related with frontline use of ICIs in advanced non-small cell lung cancer
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here
